Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G. Janssen J, et al. Among authors: heim d. Cancers (Basel). 2021 Feb 7;13(4):672. doi: 10.3390/cancers13040672. Cancers (Basel). 2021. PMID: 33562393 Free PMC article.
Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).
Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Leupin N, et al. Among authors: heim d. Leuk Lymphoma. 2010 Apr;51(4):613-9. doi: 10.3109/10428191003624231. Leuk Lymphoma. 2010. PMID: 20218808 Clinical Trial.
Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms.
Bettens F, Passweg J, Schanz U, Chalandon Y, Heim D, Güngör T, Stussi G, Nicoloso G, Baldomero H, Gratwohl A, Tiercy JM. Bettens F, et al. Among authors: heim d. Biol Blood Marrow Transplant. 2012 Apr;18(4):608-16. doi: 10.1016/j.bbmt.2011.09.011. Epub 2011 Oct 1. Biol Blood Marrow Transplant. 2012. PMID: 21963878 Free article.
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK). Pabst T, et al. Blood. 2012 Jun 7;119(23):5367-73. doi: 10.1182/blood-2011-11-389841. Epub 2012 Mar 15. Blood. 2012. PMID: 22422824 Free article. Clinical Trial.
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).
Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chalandon Y; Swiss Group for Clinical Cancer Research (SAKK). Passweg JR, et al. Among authors: heim d. Leuk Lymphoma. 2014 Jan;55(1):87-91. doi: 10.3109/10428194.2013.790540. Epub 2013 May 2. Leuk Lymphoma. 2014. PMID: 23547838 Clinical Trial.
426 results